Ikena Oncology to Participate in Upcoming Investor Conferences
24 Mayo 2023 - 7:00AM
Ikena Oncology, Inc. (Nasdaq: IKNA, “Ikena”), a targeted oncology
company forging new territory in patient-directed cancer treatment,
today announced that management will participate in TD Cowen’s 4th
Annual Oncology Innovation Summit taking place May 30-31, 2023, and
the Jefferies Healthcare Conference taking place June 7-9, 2023.
Details are as follows:
TD Cowen’s 4th Annual Oncology Innovation
SummitFireside Chat: Wednesday, May 31, 2023 at 9:00 a.m.
– 9:25 a.m. ETWebcast Link
Jefferies Healthcare ConferencePresentation:
Thursday, June 8, 2023, 12:30 p.m. – 12:55 p.m. ETWebcast Link
The webcasts can be accessed by visiting the Investors &
Media section of the company’s website at
www.ikenaoncology.com.
About Ikena OncologyIkena Oncology™ is focused
on developing differentiated therapies for patients in need that
target nodes of cancer growth, spread, and therapeutic resistance
in the Hippo and RAS onco-signaling network. The Company’s lead
targeted oncology program, IK-930, is a TEAD1 selective Hippo
pathway inhibitor, a known tumor suppressor pathway that also
drives resistance to multiple targeted therapies. The Company’s
additional research spans other targets in the Hippo pathway as
well as the RAS signaling pathway, including developing IK-595, a
novel MEK-RAF inhibitor. Additionally, IK-175, an AHR antagonist,
is being developed in collaboration with Bristol Myers Squibb.
Ikena aims to utilize their depth of institutional knowledge and
breadth of tools to efficiently develop the right drug using the
right modality for the right patient. To learn more, visit
www.ikenaoncology.com or follow us on Twitter and LinkedIn.
Forward-Looking StatementsThis press release
contains forward-looking statements within the meaning of the
Private Securities Litigation Reform Act of 1995, as amended,
including, without limitation, implied and express statements
regarding: the anticipated use of proceeds from the underwritten
offering, statements regarding the completion of the offering, the
timing and advancement of our targeted oncology programs, including
the timing of updates; our expectations regarding the therapeutic
benefit of our targeted oncology programs; our ability to
efficiently discover and develop product candidates; our ability to
obtain and maintain regulatory approval of our product candidates;
the implementation of our business model, expectations with respect
to cash runway, and strategic plans for our business and product
candidates. The words “may,” “will,” “could,” “would,” “should,”
“expect,” “plan,” “anticipate,” “intend,” “believe,” “estimate,”
“predict,” “project,” “potential,” “continue,” “target” and similar
expressions are intended to identify forward-looking statements,
although not all forward-looking statements contain these
identifying words. Any forward-looking statements in this press
release are based on management’s current expectations and beliefs
and are subject to a number of risks, uncertainties and important
factors that may cause actual events or results to differ
materially from those expressed or implied by any forward-looking
statements contained in this press release, including, without
limitation, those risks and uncertainties related to the timing and
advancement of our targeted oncology programs; our expectations
regarding the therapeutic benefit of our targeted oncology
programs; expectations regarding our new executive officer; our
ability to efficiently discover and develop product candidates; the
implementation of our business model, and strategic plans for our
business and product candidates, the sufficiency of the Company’s
capital resources to fund operating expenses and capital
expenditure requirements and the period in which such resources are
expected to be available, and other factors discussed in the “Risk
Factors” section of Ikena’s Quarterly Report on Form 10-Q for the
quarter ended March 31, 2023, which is on file with the SEC, as
updated by any subsequent SEC filings. We caution you not to place
undue reliance on any forward-looking statements, which speak only
as of the date they are made. We disclaim any obligation to
publicly update or revise any such statements to reflect any change
in expectations or in events, conditions or circumstances on which
any such statements may be based, or that may affect the likelihood
that actual results will differ from those set forth in the
forward-looking statements. Any forward-looking statements
contained in this press release represent our views only as of the
date hereof and should not be relied upon as representing its views
as of any subsequent date. We explicitly disclaim any obligation to
update any forward-looking statements.Investor
Contact:Rebecca CohenIkena
Oncologyrcohen@ikenaoncology.com
Media Contact:Luke ShiploLifeSci
Communicationslshiplo@lifescicomms.com
Ikena Oncology (NASDAQ:IKNA)
Gráfica de Acción Histórica
De May 2024 a Jun 2024
Ikena Oncology (NASDAQ:IKNA)
Gráfica de Acción Histórica
De Jun 2023 a Jun 2024